OS Therapies (OSTX)
1.39
-0.15 (-9.74%)
At close: Apr 04, 2025, 3:41 PM
-9.74% (1D)
| Bid | 1.36 |
| Market Cap | 30.11M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.35 |
| PE Ratio (ttm) | -3.97 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.42 |
| Volume | 161,450 |
| Avg. Volume (20D) | 1,184,019 |
| Open | 1.55 |
| Previous Close | 1.54 |
| Day's Range | 1.36 - 1.56 |
| 52-Week Range | 1.33 - 7.00 |
| Beta | -5.96 |
About OSTX
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive ...
Industry Biotechnology
Sector Healthcare
IPO Date Aug 1, 2024
Employees 3
Stock Exchange NYSE
Ticker Symbol OSTX
Website https://ostherapies.com
Analyst Forecast
According to 4 analyst ratings, the average rating for OSTX stock is "Buy." The 12-month stock price forecast is $19.5, which is an increase of 1303.08% from the latest price.
Stock Forecasts1 day ago
+13.53%
OS Therapies shares are trading higher after Lake ...
Unlock content with
Pro Subscription
1 month ago
+12.06%
OS Therapies shares are trading higher after the company announced agreements for the commercial manufacture of OST-HER2.
